CL2020003028A1 - Anticuerpos anti-cd33, anticuerpos bispecíficos anti-cd33/anti-cd3 y sus usos. - Google Patents

Anticuerpos anti-cd33, anticuerpos bispecíficos anti-cd33/anti-cd3 y sus usos.

Info

Publication number
CL2020003028A1
CL2020003028A1 CL2020003028A CL2020003028A CL2020003028A1 CL 2020003028 A1 CL2020003028 A1 CL 2020003028A1 CL 2020003028 A CL2020003028 A CL 2020003028A CL 2020003028 A CL2020003028 A CL 2020003028A CL 2020003028 A1 CL2020003028 A1 CL 2020003028A1
Authority
CL
Chile
Prior art keywords
antibodies
bispecific
antigen
methods
bispecific antibodies
Prior art date
Application number
CL2020003028A
Other languages
English (en)
Inventor
Francois Gaudet
Priyanka Nair-Gupta
Michael Diem
Ronan Mcdaid
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CL2020003028A1 publication Critical patent/CL2020003028A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describen anticuerpos anti-CD33 y fragmentos de unión al antígeno de estos y anticuerpos biespecíficos anti-CD33/anti-CD3 o fragmentos de unión al antígeno de estos. También se describen ácidos nucleicos que codifican los anticuerpos, composiciones que comprenden los anticuerpos, métodos para producir los anticuerpos y métodos para usar los anticuerpos para tratar o prevenir enfermedades, tales como el cáncer.
CL2020003028A 2018-05-24 2020-11-20 Anticuerpos anti-cd33, anticuerpos bispecíficos anti-cd33/anti-cd3 y sus usos. CL2020003028A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862676123P 2018-05-24 2018-05-24
US201962825846P 2019-03-29 2019-03-29

Publications (1)

Publication Number Publication Date
CL2020003028A1 true CL2020003028A1 (es) 2021-04-16

Family

ID=67211770

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020003028A CL2020003028A1 (es) 2018-05-24 2020-11-20 Anticuerpos anti-cd33, anticuerpos bispecíficos anti-cd33/anti-cd3 y sus usos.

Country Status (23)

Country Link
US (1) US11466082B2 (es)
EP (1) EP3802606B1 (es)
JP (1) JP7530298B2 (es)
KR (1) KR102890653B1 (es)
CN (1) CN112189022B (es)
AU (1) AU2019274229B2 (es)
BR (1) BR112020023357A2 (es)
CL (1) CL2020003028A1 (es)
CO (1) CO2020014575A2 (es)
CR (1) CR20200567A (es)
EC (1) ECSP20075198A (es)
ES (1) ES2998890T3 (es)
IL (1) IL278844A (es)
JO (1) JOP20190116A1 (es)
MA (1) MA52771A (es)
MX (1) MX2020012588A (es)
NI (1) NI202000088A (es)
PE (1) PE20210180A1 (es)
PH (1) PH12020552010A1 (es)
SG (1) SG11202011210TA (es)
TW (1) TW202033551A (es)
UY (1) UY38242A (es)
WO (1) WO2019224711A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201792581A1 (ru) 2015-05-29 2018-07-31 Амфивена Терапьютикс, Инк. Способы применения биспецифических cd33- и cd3- связывающих белков
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
MX420253B (es) 2018-05-24 2025-02-10 Janssen Biotech Inc Anticuerpos anti-cd3 y usos de estos.
SG11202101552SA (en) 2018-08-31 2021-03-30 Alector Llc Anti-cd33 antibodies and methods of use thereof
DE102018127845A1 (de) 2018-11-07 2020-05-07 Grimme Landmaschinenfabrik Gmbh & Co. Kg Verfahren zur Regelung des Betriebs einer Maschine zum Ernten von Hackfrüchten
CN114502584B (zh) * 2019-02-22 2025-01-10 纪念斯隆凯特琳癌症中心 Cd33抗体和使用所述抗体治疗癌症的方法
JP2022521551A (ja) 2019-02-26 2022-04-08 ツイスト バイオサイエンス コーポレーション Ｇｌｐ１受容体の変異体核酸ライブラリ
BR112022011235A2 (pt) 2019-12-09 2022-12-13 Twist Bioscience Corp Bibliotecas de variantes de ácido nucleico para receptores de adenosina
CA3173268A1 (en) * 2020-02-27 2021-09-02 Janssen Biotech, Inc. Materials and methods for modulating an immune response
US20210284731A1 (en) * 2020-03-13 2021-09-16 Janssen Biotech, Inc. Methods and materials for modulating an immune response
US20240293453A1 (en) * 2020-03-13 2024-09-05 Janssen Biotech, Inc. Materials and methods for binding siglec-3/cd33
CN115605512A (zh) * 2020-03-13 2023-01-13 詹森生物科技公司（Us） 用于调节δ链介导的免疫的材料和方法
CA3172691A1 (en) 2020-03-31 2021-10-07 Cameron J. Turtle Chimeric antigen receptors targeting cd33
EP4126925A4 (en) * 2020-03-31 2024-07-24 Fred Hutchinson Cancer Center CHIMERIC ANTIGEN RECEPTORS TARGETED AGAINST CD33
WO2021202726A2 (en) * 2020-03-31 2021-10-07 Fred Hutchinson Cancer Research Center Anti-cd33 antibodies and uses thereof
WO2021231237A2 (en) * 2020-05-11 2021-11-18 Augmenta Bioworks, Inc. Antibodies for sars-cov-2 and uses thereof
IL298444A (en) 2020-05-27 2023-01-01 Janssen Biotech Inc Proteins containing cd3 antigen binding sites and uses thereof
EP4214233A1 (en) 2020-09-16 2023-07-26 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
KR20230147617A (ko) * 2021-01-21 2023-10-23 트위스트 바이오사이언스 코포레이션 아데노신 수용체에 관한 방법 및 조성물
PE20241170A1 (es) 2021-02-16 2024-05-28 Janssen Pharmaceutica Nv Anticuerpo triespecifico dirigido a bcma, gprc5d, y cd3
BR112023019484A2 (pt) 2021-03-24 2023-12-05 Janssen Biotech Inc Anticorpo triespecífico que tem como alvo cd79b, cd20 e cd3
WO2022228471A1 (zh) * 2021-04-27 2022-11-03 上海驯鹿生物技术有限公司 一种基因编辑的造血干细胞及其与car-t细胞的联合应用
EP4377354A4 (en) * 2021-07-30 2026-01-21 Nanjing Legend Biotech Co Ltd Anti-CD33 antibodies and their uses
CN118234750A (zh) * 2021-09-02 2024-06-21 纪念斯隆-凯特琳癌症中心 抗cd33抗体和其用途
US20240409634A1 (en) * 2021-09-13 2024-12-12 Janssen Biotech, Inc. CD33 x Vd2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER
WO2023081898A1 (en) * 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy
JP2026502768A (ja) * 2022-10-25 2026-01-27 アブレクシス， エルエルシー 抗ｃｄ３抗体
WO2025120583A2 (en) * 2023-12-08 2025-06-12 Janssen Biotech, Inc. CD33 ANTIBODIES, CD33/Vδ2 MULTISPECIFIC ANTIBODIES AND USES THEREOF
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025174974A1 (en) * 2024-02-14 2025-08-21 Bristol-Myers Squibb Company Anti-cd33 antibodies and uses thereof
CN118221826B (zh) * 2024-04-25 2024-11-15 北京绿竹生物技术股份有限公司 一种结合人cd33和cd3的双特异性抗体
WO2026006495A1 (en) 2024-06-25 2026-01-02 Alloy Therapeutics, Inc. Anti-wt1/hla-a2 antibody and uses thereof
WO2026006492A2 (en) 2024-06-25 2026-01-02 Ypsilon Therapeutics, Inc. Anti-prame/hla-a2 antibodies and uses thereof
CN119804863B (zh) * 2025-03-13 2025-06-17 北京华诺泰生物医药科技有限公司 检测人偏肺病毒抗原的酶联免疫试剂盒及定量检测方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DK1578446T3 (en) 2002-11-07 2015-06-29 Immunogen Inc ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT
AU2005282700A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
AU2008234019B2 (en) 2007-04-03 2014-05-29 Amgen Research (Munich) Gmbh Cross-species-specific bispecific binders
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
RU2769948C2 (ru) 2007-04-03 2022-04-11 Эмджен Рисерч (Мьюник) Гмбх CD3-Эпсилон-связывающий домен с межвидовой специфичностью
EP3106468A1 (en) 2008-10-01 2016-12-21 Amgen Research (Munich) GmbH Cross-species-specific psmaxcd3 bispecific single chain antibody
AU2009299794B2 (en) 2008-10-01 2015-08-13 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
AU2009299793B2 (en) 2008-10-01 2016-03-10 Amgen Research (Munich) Gmbh Bispecific single chain antibodies with specificity for high molecular weight target antigens
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
PL2560993T3 (pl) 2010-04-20 2024-11-04 Genmab A/S Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
AU2012332021B8 (en) 2011-11-04 2017-10-12 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
US20130309223A1 (en) * 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
EP4269602A3 (en) 2012-12-14 2023-12-27 OmniAB, Inc. Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
AR097648A1 (es) * 2013-09-13 2016-04-06 Amgen Inc Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
MX2016007576A (es) 2013-12-13 2016-10-03 Genentech Inc Anticuerpos e inmunoconjugados anti-cd33.
US9212225B1 (en) 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
JO3568B1 (ar) * 2014-09-05 2020-07-05 Janssen Pharmaceutica Nv عوامل ربط cd123 واستخداماتها
EP3307779A2 (en) * 2015-06-12 2018-04-18 Alector LLC Anti-cd33 antibodies and methods of use thereof
CA2988982A1 (en) * 2015-06-12 2016-12-15 Alector Llc Anti-cd33 antibodies and methods of use thereof
AU2018310985A1 (en) 2017-08-03 2019-11-07 Alector Llc Anti-CD33 antibodies and methods of use thereof
CA3091764A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Antibody variable domains targeting cd33, and use thereof
MX420253B (es) * 2018-05-24 2025-02-10 Janssen Biotech Inc Anticuerpos anti-cd3 y usos de estos.

Also Published As

Publication number Publication date
NI202000088A (es) 2021-03-23
JP2021524244A (ja) 2021-09-13
EP3802606A2 (en) 2021-04-14
CR20200567A (es) 2021-01-20
UY38242A (es) 2019-11-29
WO2019224711A3 (en) 2020-01-02
BR112020023357A2 (pt) 2021-04-27
SG11202011210TA (en) 2020-12-30
US20190382481A1 (en) 2019-12-19
AU2019274229B2 (en) 2026-03-19
AU2019274229A1 (en) 2020-11-26
CN112189022B (zh) 2025-04-15
ES2998890T3 (en) 2025-02-24
KR102890653B1 (ko) 2025-11-24
WO2019224711A2 (en) 2019-11-28
PE20210180A1 (es) 2021-01-29
US11466082B2 (en) 2022-10-11
MA52771A (fr) 2021-04-14
EP3802606B1 (en) 2024-10-09
CN112189022A (zh) 2021-01-05
ECSP20075198A (es) 2020-12-31
JOP20190116A1 (ar) 2019-11-24
MX2020012588A (es) 2021-04-28
KR20210013156A (ko) 2021-02-03
IL278844A (en) 2021-01-31
PH12020552010A1 (en) 2021-06-14
CA3101270A1 (en) 2019-11-28
CO2020014575A2 (es) 2020-12-10
TW202033551A (zh) 2020-09-16
JP7530298B2 (ja) 2024-08-07

Similar Documents

Publication Publication Date Title
CL2020003028A1 (es) Anticuerpos anti-cd33, anticuerpos bispecíficos anti-cd33/anti-cd3 y sus usos.
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
CL2019002566A1 (es) Anticuerpos anti-phf-tau y usos de estos.
MX2020011914A (es) Anticuerpos anti-dll3 y usos de los mismos.
DOP2021000229A (es) Materiales y métodos para modular la inmunidad mediada por cédula t
ECSP18011248A (es) Diacuerpos monovalentes biespecíficos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos
PE20210488A1 (es) Anticuerpos especificos para gucy2c y sus usos
MX2017006167A (es) Compuestos que interactúan con glicanos y métodos de uso.
PE20191846A1 (es) Anticuerpos especificos para flt3 y sus usos
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
CO2019012329A2 (es) Polipéptidos que antagonizan la señalización wnt en células tumorales
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
MX391279B (es) Anticuerpos biespecíficos contra cd3 y cd20.
MX2016015456A (es) Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos.
MX2016006232A (es) Anticuerpos especificos para el ligando 1a tipo factor de necrosis tumoral y composiciones y usos de los mismos.
CL2018002810A1 (es) Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada.
MX375119B (es) Anticuerpos contra tau y sus usos.
MX2022012628A (es) Anticuerpos anti-phf-tau y usos de estos.
CL2021001615A1 (es) Anticuerpos anti il-36 y procedimientos de uso de estos
MX2019007161A (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
EA202190807A1 (ru) Антитела к синуклеину
UY39699A (es) Anticuerpos anti-tau y usos de estos
EA202092122A1 (ru) Антитела против tip-1 и их применения
MX2021009767A (es) Moleculas de union de fmcr y usos de las mismas.
AR115424A1 (es) Anticuerpos anti-cd33, anticuerpos biespecíficos anti-cd33 / anti-cd3 y usos de estos